Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

Updates regarding government operating status and resumption of normal operations can be found at

News Releases

Showing results filtered by:

December 2014

November 2014

October 2014

  • Model by NIH Grantees Explains Why HIV Prevention Dosing Differs by Sex

    October 30, 2014

    A mathematical model developed by NIH grantees predicts that women must take the antiretroviral medication Truvada daily to prevent HIV infection via vaginal sex, whereas just two doses per week can protect men from HIV infection via anal sex.

  • NIH-Led Study Explores Prevention of Heart Disease in HIV-Infected People

    October 28, 2014

    ​The National Institutes of Health has launched a clinical trial to assess the effects of aspirin and cholesterol-lowering drugs, or statins, on preventing cardiovascular disease in people with long-term HIV infections. This group, which includes people on antiretroviral therapy (ART) as well as "elite controllers" who can limit the virus without ART, have a higher risk of developing heart disease and stroke compared to the general population. The study is funded by NIH's National Institute of Allergy and Infectious Diseases (NIAID).

  • BULLETIN: In South Africa, RV144 HIV Vaccine Regimen Induces Immune Responses Similar to Those Seen in Thailand

    October 28, 2014

    ​The investigational HIV vaccine regimen that showed a modestly protective effect in the landmark RV144 clinical trial conducted in Thailand was shown to be safe and elicited robust immune responses when tested among 100 healthy adults in South Africa, according to findings presented today at the HIVR4P conference in Cape Town, South Africa. The results from the trial, called HVTN 097, bode well for plans to test a similar experimental vaccine regimen in South Africa beginning in 2015 in an effort to build upon the results of the RV144 study.

  • NIH Begins Early Human Clinical Trial of VSV Ebola Vaccine

    October 22, 2014

    ​Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health's Clinical Center in Bethesda, Maryland.

  • NIH Grants License Agreement for Candidate Ebola Vaccines

    October 15, 2014

    The National Institute of Allergy and Infectious Diseases today announced a new license agreement aimed at advancing dual-purpose candidate vaccines to protect against rabies and Ebola viruses. 

  • Gene Therapy Shows Promise for Severe Combined Immunodeficiency

    October 8, 2014

    Researchers have found that gene therapy using a modified delivery system, or vector, can restore the immune systems of children with X-linked severe combined immunodeficiency (SCID-X1).

  • NIH-Supported Scientists Unveil Structure, Dynamics of Key HIV Molecules

    October 8, 2014

    New research has illuminated the movement and complete structure of the spikes on HIV that the virus uses to bind to the cells it infects.

  • Candidate H7N9 Avian Flu Vaccine Works Better with Adjuvant

    October 7, 2014

    ​An experimental vaccine to protect people against H7N9 avian influenza prompted immune responses in 59 percent of volunteers who received two injections at the lowest dosage tested but only if the vaccine was mixed with adjuvant. 

September 2014

August 2014

  • NIH to Launch Human Safety Study of Ebola Vaccine Candidate

    August 28, 2014

    ​Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin next week by the National Institute of Allergy and Infectious Disease, part of the National Institutes of Health.

  • HIV Antibodies Block Infection by Reservoir-Derived Virus in Laboratory Study

    August 26, 2014

    A laboratory study led by scientists from the National Institute of Allergy and Infectious Diseases lends further weight to the potential effectiveness of passive immunotherapy to suppress HIV in the absence of drug treatment.

  • NIH Scientists Establish New Monkey Model of Severe MERS-CoV Disease

    August 21, 2014

    NIH scientists have found that Middle East respiratory syndrome coronavirus infection in marmosets closely mimics the severe pneumonia experienced by people infected with MERS-CoV, giving scientists the best animal model for testing potential treatments.

  • Test Reliably Detects Inherited Immune Deficiency in Newborns

    August 20, 2014

    A newborn screening test for severe combined immunodeficiency (SCID) reliably identifies infants with this life-threatening inherited condition, leading to prompt treatment and high survival rates, according to a study supported by the National Institutes of Health. Researchers led by Jennifer Puck, M.D., of the University of California, San Francisco, also found that SCID affects approximately 1 in 58,000 newborns, indicating that the disorder is less rare than previously thought.

  • Experimental Chikungunya Vaccine Induces Robust Antibody Response

    August 14, 2014

    An experimental vaccine to prevent the mosquito-borne viral illness chikungunya elicited neutralizing antibodies in volunteers who participated in an early-stage clinical trial conducted by researchers at the National Institute of Allergy and Infectious Diseases.

  • Ebola Outbreak Highlights Global Disparities in Healthcare Resources

    August 13, 2014

    The outbreak of Ebola virus disease that has claimed more than 1,000 lives in West Africa this year poses a serious, ongoing threat to that region: the spread to capital cities and Nigeria..

  • NIH-Led Scientists Boost Potential of Passive Immunization Against HIV

    August 13, 2014

    Scientists are pursuing injections or intravenous infusions of broadly neutralizing HIV antibodies (bNAbs) as a strategy for preventing HIV infection.

  • NIH and Italian Scientists Develop Nasal Test for Human Prion Disease

    August 6, 2014

    A nasal brush test can rapidly and accurately diagnose Creutzfeldt-Jakob disease, an incurable and ultimately fatal neurodegenerative disorder, according to a study by National Institutes of Health scientists and their Italian colleagues.

July 2014

June 2014

May 2014

April 2014

March 2014

February 2014

January 2014